动物疫苗市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024 年全球动物疫苗市场价值为 99 亿美元，预计到 2034 年将以 6.9% 的复合年增长率成长，达到 190 亿美元。随着人们对动物健康和食品安全的担忧日益加剧，全球对动物疫苗的需求也上升。随着人们越来越重视预防人畜共通传染病和减少动物疾病爆发造成的经济损失，疫苗接种计画的重要性也倍增。全球动物数量的稳定增长，以及宠物收养和拥有趋势的不断增长，正在重塑人们对兽医护理的看法和优先考虑方式。如今，宠物主人更倾向于投资预防性医疗保健，包括接种疫苗，以确保他们的伴侣动物寿命更长、更健康。同时，畜牧农民正在采取积极的免疫策略，保护他们的牲畜免受可能破坏供应链并影响国际贸易的高度传染性疾病的侵害。世界各国政府都在加强与动物健康相关的法规，实施强制疫苗接种计划，以保护动物福利，确保食品供应链安全，并最大限度地降低跨物种疾病传播的风险。人们越来越认识到动物健康是公共卫生不可或缺的一部分，这对市场成长做出了巨大贡献。

动物疫苗市场大致分为两大类：牲畜和伴侣动物。 2024 年，牲畜类别占据市场主导地位，估值达 64 亿美元。家禽、牛、猪和水产养殖等牲畜对全球粮食安全和农业经济至关重要。预防这些动物的疾病爆发对于维持生产力和减少经济损失至关重要。口蹄疫、猪瘟和禽流感的发生率仍然是该领域的严重问题，因此需要强而有力的疫苗接种策略。虽然随着宠物拥有量的增加和对宠物健康的关注度增加，伴侣动物细分市场也不断扩大，但牲畜细分市场仍创造最高收入。

动物保健领域的疫苗包括几种类型，例如减毒活疫苗、结合疫苗、灭活疫苗、DNA疫苗、重组疫苗等。其中，减毒活疫苗在2024年市占率最高，占44.1%。这些疫苗因其能够产生强大的免疫反应并提供长期保护而受到广泛青睐。它们能够刺激体液和细胞介导的免疫，从而减少重复剂量的需要，使其成为牲畜和伴侣动物疫苗接种计划的首选。

2024 年，北美占全球动物疫苗市场的 40.6%。这一主导份额是由于该地区拥有大量的家畜和牲畜。美国是宠物拥有量最高的国家，拥有成熟的农业部门，包括牛、家禽和猪。对维护畜群健康和最大限度降低传染病风险的持续关注继续推动该地区疫苗的采用。

影响全球动物疫苗模式的主要参与者包括 Zoetis、默克动物保健、维克、勃林格殷格翰国际、Bioveta、Brilliant Bio Pharma、Dechra Pharmaceuticals、Vetoquinol、Neogen Corporation、Elanco Animal Health、Hipra Animal Health Limited 和 Henry Schein Animal Health（Covetrus, Inc.）。这些公司正在透过广泛的研究和开发积极扩大其疫苗组合。与兽医组织和政府机构的策略伙伴关係有助于提高疫苗的可及性。此外，采用基因工程和重组 DNA 等先进技术，可以研发出针对不断演变的疾病威胁的更有效、更持久的疫苗。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 人畜共通传染病发生率上升
    • 畜牧业扩张与食品安全问题
    • 增加宠物收养和动物健康支出
    • 疫苗技术的进步
    • 动物疾病爆发增多
  • 产业陷阱与挑战
    • 开发成本高
    • 严格的监管要求
• 成长潜力分析
• 监管格局
• 产品线分析
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：按动物类型，2021 - 2034 年

• 主要趋势
• 牲畜
  • 家禽
  • 牛
  • 猪
  • 水产养殖
  • 绵羊和山羊
• 伴侣动物
  • 犬科动物
  • 猫科动物
  • 马
  • 禽类

第六章：市场估计与预测：按疫苗类型，2021 - 2034 年

• 主要趋势
• 减毒活疫苗
• 结合疫苗
• 灭活疫苗
• DNA疫苗
• 重组疫苗
• 其他疫苗类型

第七章：市场估计与预测：按应用，2021 - 2034 年

• 主要趋势
• 细菌感染
• 病毒感染
• 寄生虫感染
• 霉菌感染
• 其他应用

第八章：市场估计与预测：按管理路线，2021 - 2034 年

• 主要趋势
• 注射疫苗
• 口服疫苗
• 浸入式/喷雾式疫苗

第九章：市场估计与预测：按配销通路，2021 - 2034 年

• 主要趋势
• 兽医院药房
• 零售药局
• 电子商务

第十章：市场估计与预测：按地区，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：公司简介

• Boehringer Ingelheim International
• Brilliant Bio Pharma
• Bioveta
• Ceva Sante Animale
• Durvet
• Dechra Pharmaceuticals
• Elanco Animal Health
• Henry Schein Animal Health (Covetrus, Inc.)
• Hipra Animal Health Limited
• Indian Immunologicals
• Merck Animal Health
• Neogen Corporation
• Vetoquinol
• Virbac
• Zoetis

The Global Animal Vaccines Market was valued at USD 9.9 billion in 2024 and is estimated to grow at a CAGR of 6.9% to reach USD 19 billion by 2034. The global demand for animal vaccines is on the rise as concerns over animal health and food safety gain increasing prominence. With the growing emphasis on preventing zoonotic diseases and reducing economic losses from animal disease outbreaks, the importance of vaccination programs has grown multifold. A steady rise in the global animal population, along with the increasing trend of pet adoption and ownership, is reshaping how veterinary care is perceived and prioritized. Pet owners today are more inclined to invest in preventive healthcare, including vaccinations, to ensure longer and healthier lives for their companion animals. At the same time, livestock farmers are adopting proactive immunization strategies to safeguard their herds against highly contagious diseases that can cripple supply chains and impact international trade. Governments across the globe are tightening regulations related to animal health, implementing compulsory vaccination programs to protect animal welfare, secure the food supply chain, and minimize the risk of cross-species disease transmission. This broader awareness of animal health as an integral part of public health is significantly contributing to market growth.

The animal vaccines market is broadly segmented into two key categories: livestock and companion animals. In 2024, the livestock category dominated the market with a valuation of USD 6.4 billion. Livestock species such as poultry, cattle, swine, and aquaculture are critical to global food security and agricultural economies. Preventing disease outbreaks in these animals is crucial to maintaining productivity and minimizing financial losses. Incidences of foot-and-mouth disease, swine fever, and avian influenza remain serious concerns in this sector, reinforcing the need for robust vaccination strategies. While the companion animal segment is also expanding due to rising pet ownership and increased attention to pet wellness, the livestock segment continues to generate the highest revenue.

Vaccines in the animal health sector include several types, such as attenuated live, conjugate, inactivated, DNA, recombinant, and others. Among these, attenuated live vaccines held the highest market share in 2024, accounting for 44.1% of the total. These vaccines are widely favored for their ability to produce strong immune responses and deliver long-term protection. Their capability to stimulate both humoral and cell-mediated immunity often reduces the need for repeated doses, making them a preferred option in both livestock and companion animal vaccination programs.

North America accounted for 40.6% of the global animal vaccines market in 2024. This dominant share is driven by a large population of domesticated animals and livestock in the region. The United States leads in pet ownership and has a well-established agricultural sector comprising cattle, poultry, and swine. The ongoing focus on maintaining herd health and minimizing infectious disease risks continues to drive vaccine adoption in the region.

Key players shaping the global animal vaccine landscape include Zoetis, Merck Animal Health, Virbac, Boehringer Ingelheim International, Bioveta, Brilliant Bio Pharma, Dechra Pharmaceuticals, Vetoquinol, Neogen Corporation, Elanco Animal Health, Hipra Animal Health Limited, and Henry Schein Animal Health (Covetrus, Inc.). These companies are actively expanding their vaccine portfolios through extensive research and development. Strategic partnerships with veterinary organizations and government agencies are helping improve vaccine accessibility. Additionally, the adoption of advanced technologies like genetic engineering and recombinant DNA is enabling the creation of more effective, long-lasting vaccines tailored to evolving disease threats.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of zoonotic diseases
    • 3.2.1.2 Expanding livestock industry and food security concerns
    • 3.2.1.3 Increasing pet adoption and expenditure on animal health
    • 3.2.1.4 Advancements in vaccine technology
    • 3.2.1.5 Increasing outbreaks of animal diseases
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High development costs
    • 3.2.2.2 Stringent regulatory requirements
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Product pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Animal Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Livestock animals
  • 5.2.1 Poultry
  • 5.2.2 Cattle
  • 5.2.3 Swine
  • 5.2.4 Aquaculture
  • 5.2.5 Sheep and goats
• 5.3 Companion animals
  • 5.3.1 Canine
  • 5.3.2 Feline
  • 5.3.3 Equine
  • 5.3.4 Avian

Chapter 6 Market Estimates and Forecast, By Vaccine Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Attenuated live vaccine
• 6.3 Conjugate vaccine
• 6.4 Inactivated vaccine
• 6.5 DNA vaccine
• 6.6 Recombinant vaccine
• 6.7 Other vaccine types

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Bacterial infections
• 7.3 Viral infections
• 7.4 Parasitic infections
• 7.5 Fungal infections
• 7.6 Other applications

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Injection vaccines
• 8.3 Oral vaccines
• 8.4 Immersion/spray vaccines

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Veterinary hospital pharmacies
• 9.3 Retail pharmacies
• 9.4 E-commerce

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Boehringer Ingelheim International
• 11.2 Brilliant Bio Pharma
• 11.3 Bioveta
• 11.4 Ceva Sante Animale
• 11.5 Durvet
• 11.6 Dechra Pharmaceuticals
• 11.7 Elanco Animal Health
• 11.8 Henry Schein Animal Health (Covetrus, Inc.)
• 11.9 Hipra Animal Health Limited
• 11.10 Indian Immunologicals
• 11.11 Merck Animal Health
• 11.12 Neogen Corporation
• 11.13 Vetoquinol
• 11.14 Virbac
• 11.15 Zoetis